Voluntary announcement increase in shareholding by the controlling shareholder
Filed with HKEX · Stock code 2157 · · 2 pages · English
Summary by 6ix AI
This filing is a voluntary announcement regarding an increase in shareholding by the controlling shareholder of Lepu Biopharma Co. Ltd.. Dr. Pu Zhongjie, the chairman and controlling shareholder, has purchased additional shares in the company, demonstrating his confidence in its future prospects. Following this purchase, Dr. Pu holds a significant percentage of the company's total issued shares, ensuring compliance with public float requirements. Shareholders and potential investors are advised to exercise caution when trading the company's shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/voluntary-announcement-increase-in-shareholding-by-the-controlling-shareholder-1
Lepu Biopharma Co. Ltd. on 6ix
Earlier from Lepu Biopharma
- Voluntary announcement CMG901 (AZD0901) clinical results presented as lba proffered paper at presidential symposium, MRG007 clinical results presented as lba, and encouraging data for MRG003 presented as rapid oral at esmo 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement four clinical studies selected for presentation at 2026 ESMO congress: CMG901 (AZD0901) clinical trial results selected as LBA for proffered paper presentation at Presidential Symposium, MRG007 clinical trial results selected as LBA for rapid oral presentation, and two other studies selected for rapid oral presentation
- 2026 Interim Report
- BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
Follow Lepu Biopharma into a list and get an email when it puts out news.
Follow Lepu Biopharma